Clinical trials: Chronic Pulmonary Obstruction
Pulmonary Disease, Chronic Obstructive
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The primary purpose of this study is to evaluate lung function and health related quality of life (HRQoL) after 84 days of treatment with a single inhaler triple therapy combination of FF/UMEC/VI [100/62.5/25 microgram (mcg)]…
- Trial name
- NCT03478683
- Testing
- budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI
- Where
- 57 sites in United States, Czechia and 2 more
- Volunteers
- 729 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium
The objective of this study is to assess the daily variation in bronchodilator response to an inhaled short acting beta2-agonist (albuterol/salbutamol) and an inhaled short acting anticholinergic (ipratropium) individually and…
- Trial name
- NCT01691482
- Testing
- Albuterol/salbutamol, Ipratropium
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Infection, Pulmonary Disease, Chronic Obstructive
Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder
The purpose of this study is to compare the safety and pharmacokinetics of ciprofloxacin after inhalation of single 52.5 and 48.75 mg doses in COPD patients.
- Trial name
- NCT01168895
- Testing
- Cipro Inhale (Ciprofloxacin, BAYQ3939)
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease (COPD)
Study of Patient With Frequent Exacerbations in Moscow
This Study is multicenter, non-interventional, ambispective registry to evaluate the demographic and clinical characteristics, therapeutic approaches and outcomes in COPD outpatients with frequent exacerbations in Moscow
- Trial name
- CERERA-MOSCOW (NCT07307781)
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
The purpose of this study is to evaluate the lung function response to UMEC/VI, UMEC, and VI in individual patients using a cross-over design. This is a multicenter, randomized, double-blind, 3-way crossover study.
- Trial name
- NCT01716520
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Umeclidinium 62.5 mcg, Vilanterol 25 mcg
- Where
- 21 sites in Estonia, Germany
- Volunteers
- 182 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)
RV568 is being developed as a possible treatment of diseases such as smoking related lung disease (also known as Chronic Obstructive Pulmonary Disease - COPD) and asthma.
- Trial name
- NCT01475292
- Testing
- RV568
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Respivert Ltd
Emphysema
EASE Trial: Exhale Airway Stents for Emphysema
This is an international clinical research study evaluating the safety and effectiveness of a new procedure called airway bypass.
- Trial name
- EASE (NCT00391612)
- Testing
- Exhale® Drug-Eluting Stent
- Where
- 37 sites in United States, Australia and 8 more
- Volunteers
- 450 people
- Sponsor
- Broncus Technologies
Chronic Obstructive Pulmonary Disease (COPD)
Study of Patient With Frequent COPD Exacerbations
This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to therapy in outpatients with COPD and frequent…
- Trial name
- PRIORITY-COPD (NCT07221981)
- Where
- 30 sites in Russia
- Volunteers
- 2,024 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Study Comparing the Effects of Trimbow to Fostair in COPD
A randomised, open label 2-way cross-over study to compare the effects of inhaled Beclometasone/Formoterol/Glycopyrronium (TRIMBOW) pMDI to Beclometasone/Formoterol (FOSTAIR) pMDI on hyperinflation and expiratory flow limitation…
- Trial name
- TRIFLOW (NCT03842904)
- Testing
- Trimbow pMDI, Fostair pMDI
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Medicines Evaluation Unit Ltd
Healthy Participants
A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.
The study will evaluate the pharmacokinetics (PK) of AZD6793 when administered alone and in combination with itraconazole in healthy adult participants.
- Trial name
- NCT06494644
- Testing
- AZD6793, Itraconazole, AZD6793+ Itraconazole
- Where
- Germany
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Observational Study On The Characterization Of 24-Hour Symptoms In Patients With COPD
In COPD patients, a distinctive clustering of symptoms in the 3 parts of the day, early morning, day-time and night-time has been observed. These clusters are relevant to shape the health status and to explain the need of care.
- Trial name
- STORICO (NCT03105999)
- Where
- 40 sites in Italy
- Volunteers
- 683 people
- Sponsor
- Laboratori Guidotti S.p.A.
Pulmonary Disease, Chronic Obstructive
WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects
Pneumonia remains an important cause of morbidity and mortality in older adults with obstructive lung disease. Risk factors for pneumonia, including episodes associated with a hospital admission, have been extensively…
- Trial name
- NCT01763463
- Testing
- New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications, New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.
- Trial name
- NCT00622635
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Trial to investigate the acute and chronic effect of tiotropium therapy on airway diameter in COPD patients as measured by inspiratory capacity (IC).
- Trial name
- NCT02172391
- Testing
- Tiotropium inhalation powder capsules
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
This is a multi-center, randomized, double-blind, parallel-group study. The FF/VI inhalation powder once daily and VI inhalation powder once daily will be evaluated in subjects with COPD over 156 weeks.
- Trial name
- NCT01957150
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 45 sites in United States, Canada and 3 more
- Volunteers
- 283 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
The study does not involve testing of a drug (no treatment intervention). The study will will use spirometry (breathing tests) in subjects of 40 years of age and older with a history of cigarette smoking with chronic bronchitis…
- Trial name
- NCT00442468
- Testing
- Non-interventional study.
- Where
- 47 sites in United States
- Volunteers
- 1,283 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)
The purpose of this extension study is to evaluate the long-term safety, tolerability, and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe chronic obstructive pulmonary disease…
- Trial name
- NCT00970268
- Testing
- Aclidinium bromide
- Where
- 83 sites in United States, Canada
- Volunteers
- 291 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Home-based Intervention to Promote Mindful Breathing Awareness Through Pursed-lip Breathing Training for COPD Patients
The Mindful Breathing Laboratory under the direction of Dr. Benzo will complete a randomized controlled trial to evaluate the mindful breathing module.
- Trial name
- NCT05349123
- Testing
- Mindful Breathing, Home-Based Pulmonary Rehabilitation
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Minnesota HealthSolutions
Chronic Obstructive Pulmonary Disease
14729-D9831C00002- 1 Month Biopsy Study
The purpose of this study is to study histological changes, cellularity, clinical efficacy and safety of AZD1981 in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- Biopsy (NCT00766415)
- Testing
- AZD1981
- Where
- 8 sites in Germany, Netherlands and 1 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
COPD
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks treatment with AZD3199 in moderate to severe COPD.
- Trial name
- GLAD (NCT00929708)
- Testing
- AZD3199, formoterol
- Where
- 38 sites in Bulgaria, Canada and 3 more
- Volunteers
- 329 people
- Sponsor
- AstraZeneca